{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:37:58Z","timestamp":1793738278570,"version":"4.6.1"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82400428"],"award-info":[{"award-number":["No. 82400428"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation Program of Hubei Province","award":["No.2024AFB062"],"award-info":[{"award-number":["No.2024AFB062"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02707-7","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T02:37:24Z","timestamp":1743820644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF"],"prefix":"10.1186","volume":"24","author":[{"given":"Lingyun","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyue","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"10431","key":"2707_CR1","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","volume":"403","author":"P Campbell","year":"2024","unstructured":"Campbell P, Rutten FH, Lee MM, Hawkins NM, Petrie MC. Heart failure with preserved ejection fraction: everything the clinician needs to know. Lancet. 2024;403(10431):1083\u201392.","journal-title":"Lancet"},{"issue":"1","key":"2707_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","volume":"10","author":"CE Hamo","year":"2024","unstructured":"Hamo CE, DeJong C, Hartshorne-Evans N, Lund LH, Shah SJ, Solomon S, Lam CSP. Heart failure with preserved ejection fraction. Nat Rev Dis Primers. 2024;10(1):55.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"2707_CR3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","volume":"329","author":"MM Redfield","year":"2023","unstructured":"Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023;329(10):827\u201338.","journal-title":"JAMA"},{"key":"2707_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-med-042220-022745","volume":"73","author":"K Omote","year":"2022","unstructured":"Omote K, Verbrugge FH, Borlaug BA. Heart failure with preserved ejection fraction: mechanisms and treatment strategies. Annu Rev Med. 2022;73:321\u201337.","journal-title":"Annu Rev Med"},{"issue":"6","key":"2707_CR5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41569-020-00480-6","volume":"18","author":"S Mishra","year":"2021","unstructured":"Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021;18(6):400\u201323.","journal-title":"Nat Rev Cardiol"},{"issue":"18","key":"2707_CR6","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1093\/cvr\/cvac179","volume":"118","author":"AE Peters","year":"2023","unstructured":"Peters AE, Tromp J, Shah SJ, Lam CSP, Lewis GD, Borlaug BA, Sharma K, Pandey A, Sweitzer NK, Kitzman DW, et al. Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions. Cardiovasc Res. 2023;118(18):3403\u201315.","journal-title":"Cardiovasc Res"},{"key":"2707_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ahj.2016.07.025","volume":"182","author":"JB Echouffo-Tcheugui","year":"2016","unstructured":"Echouffo-Tcheugui JB, Xu H, DeVore AD, Schulte PJ, Butler J, Yancy CW, Bhatt DL, Hernandez AF, Heidenreich PA, Fonarow GC. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from get with the guidelines-heart failure registry. Am Heart J. 2016;182:9\u201320.","journal-title":"Am Heart J"},{"issue":"8","key":"2707_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.116.024593","volume":"135","author":"SL Kristensen","year":"2017","unstructured":"Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, K\u00f8ber L, McKelvie RS, Zile MR, Anand IS, et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-preserve trial (Irbesartan in heart failure with preserved ejection fraction). Circulation. 2017;135(8):724\u201335.","journal-title":"Circulation"},{"issue":"6","key":"2707_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","volume":"64","author":"BR Lindman","year":"2014","unstructured":"Lindman BR, D\u00e1vila-Rom\u00e1n VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de las Fuentes L, Joseph SM, Vader J, Hernandez AF, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64(6):541\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"2707_CR10","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1093\/cvr\/cvac166","volume":"118","author":"F Capone","year":"2023","unstructured":"Capone F, Sotomayor-Flores C, Bode D, Wang R, Rodolico D, Strocchi S, Schiattarella GG. Cardiac metabolism in HFpEF: from fuel to signalling. Cardiovasc Res. 2023;118(18):3556\u201375.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2707_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12933-024-02566-8","volume":"24","author":"A Fuerlinger","year":"2025","unstructured":"Fuerlinger A, Stockner A, Sedej S, Abdellatif M. Caloric restriction and its mimetics in heart failure with preserved ejection fraction: mechanisms and therapeutic potential. Cardiovasc Diabetol. 2025;24(1):21.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"2707_CR12","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","volume":"73","author":"K McHugh","year":"2019","unstructured":"McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, Yancy CW, Green JB, Altman N, Hernandez AF. Heart failure with preserved ejection fraction and diabetes: JACC State-of-the-Art review. J Am Coll Cardiol. 2019;73(5):602\u201311.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2707_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12933-021-01242-5","volume":"20","author":"S Lejeune","year":"2021","unstructured":"Lejeune S, Roy C, Slimani A, Pasquet A, Vancraeynest D, Vanoverschelde JL, Gerber BL, Beauloye C, Pouleur AC. Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort. Cardiovasc Diabetol. 2021;20(1):48.","journal-title":"Cardiovasc Diabetol"},{"key":"2707_CR14","doi-asserted-by":"crossref","unstructured":"Kaze AD, Bertoni AG, Fox ER, Hall ME, Mentz RJ, Berry JD, Echouffo-Tcheugui JB. Diabetes, subclinical myocardial injury or stress and risk of heart failure subtypes: the Jackson heart study. Diabetes Care; 2025.","DOI":"10.2337\/dc24-0654"},{"issue":"11","key":"2707_CR15","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1002\/ejhf.2723","volume":"24","author":"KV Patel","year":"2022","unstructured":"Patel KV, Khan MS, Segar MW, Bahnson JL, Garcia KR, Clark JM, Balasubramanyam A, Bertoni AG, Vaduganathan M, Farkouh ME, et al. Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the look AHEAD trial. Eur J Heart Fail. 2022;24(11):2037\u201347.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2707_CR16","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/ejhf.2144","volume":"23","author":"RJ Woolley","year":"2021","unstructured":"Woolley RJ, Ceelen D, Ouwerkerk W, Tromp J, Figarska SM, Anker SD, Dickstein K, Filippatos G, Zannad F, Metra M, et al. Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23(6):983\u201391.","journal-title":"Eur J Heart Fail"},{"key":"2707_CR17","doi-asserted-by":"crossref","unstructured":"Lin Y, Xie M, Zhang L, Zhang Y, Zhang P, Chen X, Ji M, Gao L, He Q, Wu Z et al. Prognostic value of LV global longitudinal strain by 2D and 3D speckle-tracking echocardiography in patients with HFpEF. Circ Cardiovasc Imaging 2025:e016975.","DOI":"10.1161\/CIRCIMAGING.124.016975"},{"issue":"3","key":"2707_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ejhf.2403","volume":"24","author":"AM Jackson","year":"2022","unstructured":"Jackson AM, R\u00f8rth R, Liu J, Kristensen SL, Anand IS, Claggett BL, Cleland JGF, Chopra VK, Desai AS, Ge J, et al. Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2022;24(3):497\u2013509.","journal-title":"Eur J Heart Fail"},{"key":"2707_CR19","doi-asserted-by":"crossref","unstructured":"Hsu JC, Yang YY, Chuang SL, Lin LY. Long-term glycemic variability predicts adverse outcomes in diabetic heart failure with preserved ejection fraction. J Clin Endocrinol Metab 2024.","DOI":"10.1210\/clinem\/dgae715"},{"issue":"1","key":"2707_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12933-024-02157-7","volume":"23","author":"AQ Mohammed","year":"2024","unstructured":"Mohammed AQ, Luo Y, Wang K, Su Y, Liu L, Yin G, Zhang W, Alifu JJ, Mareai RM, Mohammed AA, et al. Stress hyperglycemia ratio as a prognostic indicator for long-term adverse outcomes in heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2024;23(1):67.","journal-title":"Cardiovasc Diabetol"},{"key":"2707_CR21","doi-asserted-by":"publisher","first-page":"102542","DOI":"10.1016\/j.arr.2024.102542","volume":"101","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Wang Y, Chen X, Wu C, Zhou J, Chen Y, Liu X, Tang X. The aging heart in focus: the advanced Understanding of heart failure with preserved ejection fraction. Ageing Res Rev. 2024;101:102542.","journal-title":"Ageing Res Rev"},{"issue":"8","key":"2707_CR22","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1096\/fj.202000495RR","volume":"34","author":"B Tourki","year":"2020","unstructured":"Tourki B, Kain V, Shaikh SR, Leroy X, Serhan CN, Halade GV. Deficit of resolution receptor magnifies inflammatory leukocyte directed cardiorenal and endothelial dysfunction with signs of cardiomyopathy of obesity. FASEB J. 2020;34(8):10560\u201373.","journal-title":"FASEB J"},{"issue":"5","key":"2707_CR23","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s00125-024-06109-4","volume":"67","author":"M Su","year":"2024","unstructured":"Su M, Hou Y, Cai S, Li W, Wei Y, Wang R, Wu M, Liu M, Chang J, Yang K, et al. Elevated ITGA1 levels in type 2 diabetes: implications for cardiac function impairment. Diabetologia. 2024;67(5):850\u201363.","journal-title":"Diabetologia"},{"issue":"11","key":"2707_CR24","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.jchf.2023.06.031","volume":"11","author":"A Alogna","year":"2023","unstructured":"Alogna A, Koepp KE, Sabbah M, Espindola Netto JM, Jensen MD, Kirkland JL, Lam CSP, Obokata M, Petrie MC, Ridker PM, et al. Interleukin-6 in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2023;11(11):1549\u201361.","journal-title":"JACC Heart Fail"},{"issue":"10","key":"2707_CR25","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/ejhf.2291","volume":"23","author":"KP Kresoja","year":"2021","unstructured":"Kresoja KP, Rommel KP, Wachter R, Henger S, Besler C, Kl\u00f6ting N, Schnelle M, Hoffmann A, B\u00fcttner P, Ceglarek U, et al. Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23(10):1633\u201344.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"2707_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","volume":"17","author":"BA Borlaug","year":"2020","unstructured":"Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020;17(9):559\u201373.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"2707_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12933-023-02023-y","volume":"22","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Brunton SA, Rangaswami J. Sodium-glucose cotransporter-2 Inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review. Cardiovasc Diabetol. 2023;22(1):316.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2707_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1161\/CIRCULATIONAHA.120.050498","volume":"143","author":"VS Hahn","year":"2021","unstructured":"Hahn VS, Knutsdottir H, Luo X, Bedi K, Margulies KB, Haldar SM, Stolina M, Yin J, Khakoo AY, Vaishnav J, et al. Myocardial gene expression signatures in human heart failure with preserved ejection fraction. Circulation. 2021;143(2):120\u201334.","journal-title":"Circulation"},{"issue":"15","key":"2707_CR29","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1161\/CIRCULATIONAHA.122.061846","volume":"147","author":"VS Hahn","year":"2023","unstructured":"Hahn VS, Petucci C, Kim MS, Bedi KC Jr., Wang H, Mishra S, Koleini N, Yoo EJ, Margulies KB, Arany Z, et al. Myocardial metabolomics of human heart failure with preserved ejection fraction. Circulation. 2023;147(15):1147\u201361.","journal-title":"Circulation"},{"issue":"9","key":"2707_CR30","first-page":"1941","volume":"26","author":"N Koleini","year":"2024","unstructured":"Koleini N, Meddeb M, Zhao L, Keykhaei M, Kwon S, Farshidfar F, Hahn VS, Pearce EL, Sharma K, Kass DA. Landscape of glycolytic metabolites and their regulating proteins in myocardium from human heart failure with preserved ejection fraction. Eur J Heart Fail. 2024;26(9):1941\u201351.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"2707_CR31","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2337\/dc21-1705","volume":"45","author":"J Morze","year":"2022","unstructured":"Morze J, Wittenbecher C, Schwingshackl L, Danielewicz A, Rynkiewicz A, Hu FB, Guasch-Ferr\u00e9 M. Metabolomics and type 2 diabetes risk: an updated systematic review and Meta-analysis of prospective cohort studies. Diabetes Care. 2022;45(4):1013\u201324.","journal-title":"Diabetes Care"},{"key":"2707_CR32","doi-asserted-by":"publisher","first-page":"154910","DOI":"10.1016\/j.metabol.2021.154910","volume":"125","author":"SS Jankauskas","year":"2021","unstructured":"Jankauskas SS, Kansakar U, Varzideh F, Wilson S, Mone P, Lombardi A, Gambardella J, Santulli G. Heart failure in diabetes. Metabolism. 2021;125:154910.","journal-title":"Metabolism"},{"key":"2707_CR33","doi-asserted-by":"publisher","first-page":"695952","DOI":"10.3389\/fcvm.2021.695952","volume":"8","author":"B Tourki","year":"2021","unstructured":"Tourki B, Halade GV. Heart failure syndrome with preserved ejection fraction is a metabolic cluster of Non-resolving inflammation in obesity. Front Cardiovasc Med. 2021;8:695952.","journal-title":"Front Cardiovasc Med"},{"key":"2707_CR34","doi-asserted-by":"publisher","first-page":"123161","DOI":"10.1016\/j.lfs.2024.123161","volume":"358","author":"W Wen","year":"2024","unstructured":"Wen W, Cao Y, Chen P, Li J, Li W, Huang G, Zheng H, Zhu X, Zhang H, Chen Y, et al. A reliable strategy for establishment of an animal model of diabetic cardiomyopathy: induction by a high-fat diet combined with single or multiple injections of low-dose streptozotocin. Life Sci. 2024;358:123161.","journal-title":"Life Sci"},{"issue":"5","key":"2707_CR35","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2337\/db14-1050","volume":"64","author":"S Sankaralingam","year":"2015","unstructured":"Sankaralingam S, Abo Alrob O, Zhang L, Jaswal JS, Wagg CS, Fukushima A, Padwal RS, Johnstone DE, Sharma AM, Lopaschuk GD. Lowering body weight in obese mice with diastolic heart failure improves cardiac insulin sensitivity and function: implications for the obesity paradox. Diabetes. 2015;64(5):1643\u201357.","journal-title":"Diabetes"},{"issue":"4","key":"2707_CR36","doi-asserted-by":"publisher","first-page":"H934","DOI":"10.1152\/ajpheart.00238.2018","volume":"315","author":"L Alex","year":"2018","unstructured":"Alex L, Russo I, Holoborodko V, Frangogiannis NG. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2018;315(4):H934\u201349.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"2707_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00395-018-0711-0","volume":"114","author":"C Riehle","year":"2018","unstructured":"Riehle C, Bauersachs J. Of mice and men: models and mechanisms of diabetic cardiomyopathy. Basic Res Cardiol. 2018;114(1):2.","journal-title":"Basic Res Cardiol"},{"issue":"5","key":"2707_CR38","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2337\/dbi23-0019","volume":"73","author":"LC Heather","year":"2024","unstructured":"Heather LC, Gopal K, Srnic N, Ussher JR. Redefining diabetic cardiomyopathy: perturbations in substrate metabolism at the heart of its pathology. Diabetes. 2024;73(5):659\u201370.","journal-title":"Diabetes"},{"issue":"9","key":"2707_CR39","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1161\/CIRCULATIONAHA.123.065603","volume":"149","author":"S-Y Xie","year":"2024","unstructured":"Xie S-Y, Liu S-Q, Zhang T, Shi W-K, Xing Y, Fang W-X, Zhang M, Chen M-Y, Xu S-C, Fan M-Q, et al. USP28 serves as a key suppressor of mitochondrial morphofunctional defects and cardiac dysfunction in the diabetic heart. Circulation. 2024;149(9):684\u2013706.","journal-title":"Circulation"},{"issue":"11","key":"2707_CR40","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1161\/CIRCRESAHA.121.318988","volume":"131","author":"X Wu","year":"2022","unstructured":"Wu X, Liu H, Brooks A, Xu S, Luo J, Steiner R, Mickelsen DM, Moravec CS, Jeffrey AD, Small EM, et al. SIRT6 mitigates heart failure with preserved ejection fraction in diabetes. Circ Res. 2022;131(11):926\u201343.","journal-title":"Circ Res"},{"issue":"11","key":"2707_CR41","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1161\/CIRCRESAHA.120.317046","volume":"128","author":"D Tong","year":"2021","unstructured":"Tong D, Schiattarella GG, Jiang N, Altamirano F, Szweda PA, Elnwasany A, Lee DI, Yoo H, Kass DA, Szweda LI, et al. NAD\u2009+\u2009repletion reverses heart failure with preserved ejection fraction. Circ Res. 2021;128(11):1629\u201341.","journal-title":"Circ Res"},{"key":"2707_CR42","doi-asserted-by":"crossref","unstructured":"Abdellatif M, Trummer-Herbst V, Koser F, Durand S, Ad\u00e3o R, Vasques-N\u00f3voa F, Freundt JK, Voglhuber J, Pricolo M-R, Kasa M et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction. Sci Transl Med 2021, 13(580).","DOI":"10.1126\/scitranslmed.abd7064"},{"issue":"22","key":"2707_CR43","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1161\/CIRCULATIONAHA.121.056589","volume":"144","author":"M Abdellatif","year":"2021","unstructured":"Abdellatif M, Sedej S, Kroemer G. NAD\u2009+\u2009metabolism in cardiac health, aging, and disease. Circulation. 2021;144(22):1795\u2013817.","journal-title":"Circulation"},{"issue":"4","key":"2707_CR44","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1161\/CIRCRESAHA.123.322381","volume":"134","author":"Y-C Wang","year":"2024","unstructured":"Wang Y-C, Koay YC, Pan C, Zhou Z, Tang W, Wilcox J, Li XS, Zagouras A, Marques F, Allayee H, et al. Indole-3-propionic acid protects against heart failure with preserved ejection fraction. Circ Res. 2024;134(4):371\u201389.","journal-title":"Circ Res"},{"issue":"13","key":"2707_CR45","doi-asserted-by":"publisher","first-page":"e020654","DOI":"10.1161\/JAHA.120.020654","volume":"10","author":"AL Beale","year":"2021","unstructured":"Beale AL, O\u2019Donnell JA, Nakai ME, Nanayakkara S, Vizi D, Carter K, Dean E, Ribeiro RV, Yiallourou S, Carrington MJ, et al. The gut Microbiome of heart failure with preserved ejection fraction. J Am Heart Assoc. 2021;10(13):e020654.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"2707_CR46","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.122.062874","volume":"147","author":"F Capone","year":"2023","unstructured":"Capone F, Vettor R, Schiattarella GG. Cardiometabolic HFpEF: NASH of the heart. Circulation. 2023;147(6):451\u20133.","journal-title":"Circulation"},{"issue":"18","key":"2707_CR47","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","volume":"118","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2023;118(18):3434\u201350.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2707_CR48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1146\/annurev-pathmechdis-111523-023405","volume":"20","author":"EB Thorp","year":"2025","unstructured":"Thorp EB, Filipp M. Contributions of inflammation to cardiometabolic heart failure with preserved ejection fraction. Annu Rev Pathol. 2025;20(1):143\u201367.","journal-title":"Annu Rev Pathol"},{"issue":"36","key":"2707_CR49","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1093\/eurheartj\/eht246","volume":"34","author":"S M\u00f8ller","year":"2013","unstructured":"M\u00f8ller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J. 2013;34(36):2804\u201311.","journal-title":"Eur Heart J"},{"issue":"4","key":"2707_CR50","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/emmm.201303800","volume":"6","author":"KK Baskin","year":"2014","unstructured":"Baskin KK, Bookout AL, Olson EN. The heart-liver metabolic axis: defective communication exacerbates disease. EMBO Mol Med. 2014;6(4):436\u20138.","journal-title":"EMBO Mol Med"},{"issue":"14","key":"2707_CR51","doi-asserted-by":"publisher","first-page":"e029873","DOI":"10.1161\/JAHA.123.029873","volume":"12","author":"K Wegermann","year":"2023","unstructured":"Wegermann K, Fudim M, Henao R, Howe CF, McGarrah R, Guy C, Abdelmalek MF, Diehl AM, Moylan CA. Serum metabolites are associated with HFpEF in biopsy-proven nonalcoholic fatty liver disease. J Am Heart Assoc. 2023;12(14):e029873.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2707_CR52","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274\u201385.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2707_CR53","doi-asserted-by":"publisher","first-page":"12440","DOI":"10.1038\/s41598-020-69013-y","volume":"10","author":"A Miller","year":"2020","unstructured":"Miller A, McNamara J, Hummel SL, Konerman MC, Tincopa MA. Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction. Sci Rep. 2020;10(1):12440.","journal-title":"Sci Rep"},{"issue":"2","key":"2707_CR54","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.amjmed.2019.09.002","volume":"133","author":"M Packer","year":"2020","unstructured":"Packer M. Atrial fibrillation and heart failure with preserved ejection fraction in patients with nonalcoholic fatty liver disease. Am J Med. 2020;133(2):170\u20137.","journal-title":"Am J Med"},{"issue":"4","key":"2707_CR55","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.dld.2021.08.017","volume":"54","author":"M Mo","year":"2022","unstructured":"Mo M, Huang Z, Liang Y, Liao Y, Xia N. The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: an updated meta-analysis. Dig Liver Dis. 2022;54(4):461\u20138.","journal-title":"Dig Liver Dis"},{"issue":"8","key":"2707_CR56","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","volume":"27","author":"GA Lewis","year":"2021","unstructured":"Lewis GA, Dodd S, Clayton D, Bedson E, Eccleson H, Schelbert EB, Naish JH, Jimenez BD, Williams SG, Cunnington C, et al. Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat Med. 2021;27(8):1477\u201382.","journal-title":"Nat Med"},{"issue":"8","key":"2707_CR57","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1161\/CIRCRESAHA.124.324829","volume":"135","author":"S Strocchi","year":"2024","unstructured":"Strocchi S, Liu L, Wang R, H\u00e4seli SP, Capone F, Bode D, Nambiar N, Eroglu T, Santiago Padilla L, Farrelly C, et al. Systems biology approach uncovers candidates for liver-heart interorgan crosstalk in HFpEF. Circ Res. 2024;135(8):873\u20136.","journal-title":"Circ Res"},{"issue":"6613","key":"2707_CR58","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1126\/science.abn0910","volume":"377","author":"Y Cao","year":"2022","unstructured":"Cao Y, Wang Y, Zhou Z, Pan C, Jiang L, Zhou Z, Meng Y, Charugundla S, Li T, Allayee H, et al. Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure. Science. 2022;377(6613):1399\u2013406.","journal-title":"Science"},{"issue":"1","key":"2707_CR59","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s41467-025-56885-9","volume":"16","author":"K Zhang","year":"2025","unstructured":"Zhang K, Gan J, Wang B, Lei W, Zhen D, Yang J, Wang N, Wen C, Gao X, Li X, et al. FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice. Nat Commun. 2025;16(1):1661.","journal-title":"Nat Commun"},{"issue":"32","key":"2707_CR60","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1093\/eurheartj\/ehab431","volume":"42","author":"L Da Dalt","year":"2021","unstructured":"Da Dalt L, Castiglioni L, Baragetti A, Audano M, Svecla M, Bonacina F, Pedretti S, Uboldi P, Benzoni P, Giannetti F, et al. PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction. Eur Heart J. 2021;42(32):3078\u201390.","journal-title":"Eur Heart J"},{"issue":"6","key":"2707_CR61","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.cmet.2024.04.020","volume":"36","author":"W Xie","year":"2024","unstructured":"Xie W, Gan J, Zhou X, Tian H, Pan X, Liu W, Li X, Du J, Xu A, Zheng M, et al. Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of Periosti. Cell Metab. 2024;36(6):1269\u2013e12861269.","journal-title":"Cell Metab"},{"issue":"14","key":"2707_CR62","doi-asserted-by":"publisher","first-page":"eade4110","DOI":"10.1126\/sciadv.ade4110","volume":"9","author":"JY Sun","year":"2023","unstructured":"Sun JY, Du LJ, Shi XR, Zhang YY, Liu Y, Wang YL, Chen BY, Liu T, Zhu H, Liu Y, et al. An IL-6\/STAT3\/MR\/FGF21 axis mediates heart-liver cross-talk after myocardial infarction. Sci Adv. 2023;9(14):eade4110.","journal-title":"Sci Adv"},{"key":"2707_CR63","doi-asserted-by":"crossref","unstructured":"Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009, 124(1).","DOI":"10.1016\/j.jaci.2009.05.038"},{"key":"2707_CR64","doi-asserted-by":"publisher","first-page":"101706","DOI":"10.1016\/j.arr.2022.101706","volume":"81","author":"T Hu","year":"2022","unstructured":"Hu T, Wu Q, Yao Q, Jiang K, Yu J, Tang Q. Short-chain fatty acid metabolism and multiple effects on cardiovascular diseases. Ageing Res Rev. 2022;81:101706.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"2707_CR65","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/s41467-022-29060-7","volume":"13","author":"M Zhao","year":"2022","unstructured":"Zhao M, Wei H, Li C, Zhan R, Liu C, Gao J, Yi Y, Cui X, Shan W, Ji L, et al. Gut microbiota production of trimethyl-5-aminovaleric acid reduces fatty acid oxidation and accelerates cardiac hypertrophy. Nat Commun. 2022;13(1):1757.","journal-title":"Nat Commun"},{"issue":"1","key":"2707_CR66","doi-asserted-by":"publisher","first-page":"e009972","DOI":"10.1161\/CIRCHEARTFAILURE.122.009972","volume":"16","author":"KA Romano","year":"2023","unstructured":"Romano KA, Nemet I, Prasad Saha P, Haghikia A, Li XS, Mohan ML, Lovano B, Castel L, Witkowski M, Buffa JA, et al. Gut microbiota-generated phenylacetylglutamine and heart failure. Circ Heart Fail. 2023;16(1):e009972.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"2707_CR67","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12933-024-02398-6","volume":"23","author":"SJ Guivala","year":"2024","unstructured":"Guivala SJ, Bode KA, Okun JG, Kartal E, Schwedhelm E, Pohl LV, Werner S, Erbs S, Thiele H, B\u00fcttner P. Interactions between the gut microbiome, associated metabolites and the manifestation and progression of heart failure with preserved ejection fraction in ZSF1 rats. Cardiovasc Diabetol. 2024;23(1):299.","journal-title":"Cardiovasc Diabetol"},{"key":"2707_CR68","doi-asserted-by":"publisher","first-page":"803744","DOI":"10.3389\/fcvm.2021.803744","volume":"8","author":"Z Huang","year":"2021","unstructured":"Huang Z, Mei X, Jiang Y, Chen T, Zhou Y. Gut microbiota in heart failure patients with preserved ejection fraction (GUMPTION Study). Front Cardiovasc Med. 2021;8:803744.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"2707_CR69","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13073-016-0296-x","volume":"8","author":"LS Zhang","year":"2016","unstructured":"Zhang LS, Davies SS. Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. Genome Med. 2016;8(1):46.","journal-title":"Genome Med"},{"issue":"6","key":"2707_CR70","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/nm.4106","volume":"22","author":"V Rothhammer","year":"2016","unstructured":"Rothhammer V, Mascanfroni ID, Bunse L, Takenaka MC, Kenison JE, Mayo L, Chao C-C, Patel B, Yan R, Blain M, et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the Aryl hydrocarbon receptor. Nat Med. 2016;22(6):586\u201397.","journal-title":"Nat Med"},{"key":"2707_CR71","doi-asserted-by":"crossref","unstructured":"Li Y, Xu W, Zhang F, Zhong S, Sun Y, Huo J, Zhu J, Wu C. The gut microbiota-produced indole-3-propionic acid confers the antihyperlipidemic effect of mulberry-derived 1-deoxynojirimycin. mSystems 2020, 5(5).","DOI":"10.1128\/mSystems.00313-20"},{"issue":"7682","key":"2707_CR72","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nature24661","volume":"551","author":"D Dodd","year":"2017","unstructured":"Dodd D, Spitzer MH, Van Treuren W, Merrill BD, Hryckowian AJ, Higginbottom SK, Le A, Cowan TM, Nolan GP, Fischbach MA, et al. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature. 2017;551(7682):648\u201352.","journal-title":"Nature"},{"issue":"2","key":"2707_CR73","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.tem.2016.10.005","volume":"28","author":"CE Cho","year":"2017","unstructured":"Cho CE, Caudill MA. Trimethylamine-N-Oxide: friend, foe, or simply caught in the cross-fire? Trends Endocrinol Metab. 2017;28(2):121\u201330.","journal-title":"Trends Endocrinol Metab"},{"issue":"8","key":"2707_CR74","doi-asserted-by":"publisher","first-page":"6745","DOI":"10.1039\/D0FO01237H","volume":"11","author":"C Sim\u00f3","year":"2020","unstructured":"Sim\u00f3 C, Garc\u00eda-Ca\u00f1as V. Dietary bioactive ingredients to modulate the gut microbiota-derived metabolite TMAO. New opportunities for functional food development. Food Funct. 2020;11(8):6745\u201376.","journal-title":"Food Funct"},{"issue":"19","key":"2707_CR75","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1177\/2047487319870355","volume":"27","author":"A Salzano","year":"2020","unstructured":"Salzano A, Israr MZ, Yazaki Y, Heaney LM, Kanagala P, Singh A, Arnold JR, Gulsin GS, Squire IB, McCann GP, et al. Combined use of trimethylamine N-oxide with BNP for risk stratification in heart failure with preserved ejection fraction: findings from the DIAMONDHFpEF study. Eur J Prev Cardiol. 2020;27(19):2159\u201362.","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"2707_CR76","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/ehf2.13290","volume":"8","author":"Y Kinugasa","year":"2021","unstructured":"Kinugasa Y, Nakamura K, Kamitani H, Hirai M, Yanagihara K, Kato M, Yamamoto K. Trimethylamine N-oxide and outcomes in patients hospitalized with acute heart failure and preserved ejection fraction. ESC Heart Fail. 2021;8(3):2103\u201310.","journal-title":"ESC Heart Fail"},{"key":"2707_CR77","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fendo.2020.00025","volume":"11","author":"YP Silva","year":"2020","unstructured":"Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne). 2020;11:25.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2707_CR78","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.2337\/db14-1213","volume":"64","author":"G den Besten","year":"2015","unstructured":"den Besten G, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk TH, Oosterveer MH, Jonker JW, Groen AK, Reijngoud D-J, et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPAR\u03b3-dependent switch from lipogenesis to fat oxidation. Diabetes. 2015;64(7):2398\u2013408.","journal-title":"Diabetes"},{"issue":"7","key":"2707_CR79","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2337\/db08-1637","volume":"58","author":"Z Gao","year":"2009","unstructured":"Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes. 2009;58(7):1509\u201317.","journal-title":"Diabetes"},{"issue":"7","key":"2707_CR80","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jacbts.2021.12.010","volume":"7","author":"AA Challa","year":"2022","unstructured":"Challa AA, Lewandowski ED. Short-chain carbon sources: exploiting pleiotropic effects for heart failure therapy. JACC Basic Transl Sci. 2022;7(7):730\u201342.","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"2707_CR81","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1046\/j.0009-9104.2002.01977.x","volume":"130","author":"AL Millard","year":"2002","unstructured":"Millard AL, Mertes PM, Ittelet D, Villard F, Jeannesson P, Bernard J. Butyrate affects differentiation, maturation and function of human monocyte-derived dendritic cells and macrophages. Clin Exp Immunol. 2002;130(2):245\u201355.","journal-title":"Clin Exp Immunol"},{"key":"2707_CR82","doi-asserted-by":"publisher","first-page":"16148","DOI":"10.1038\/srep16148","volume":"5","author":"C Nastasi","year":"2015","unstructured":"Nastasi C, Candela M, Bonefeld CM, Geisler C, Hansen M, Krejsgaard T, Biagi E, Andersen MH, Brigidi P, \u00d8dum N, et al. The effect of short-chain fatty acids on human monocyte-derived dendritic cells. Sci Rep. 2015;5:16148.","journal-title":"Sci Rep"},{"issue":"7480","key":"2707_CR83","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature12726","volume":"504","author":"N Arpaia","year":"2013","unstructured":"Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451\u20135.","journal-title":"Nature"},{"key":"2707_CR84","doi-asserted-by":"crossref","unstructured":"Huang W, Guo H-L, Deng X, Zhu T-T, Xiong J-F, Xu Y-H, Xu Y. Short-Chain fatty acids inhibit oxidative stress and inflammation in mesangial cells induced by high glucose and lipopolysaccharide. Exp Clin Endocrinol Diabetes 2017, 125(2).","DOI":"10.1055\/s-0042-121493"},{"key":"2707_CR85","doi-asserted-by":"publisher","first-page":"583175","DOI":"10.3389\/fcvm.2020.583175","volume":"7","author":"AE Berezin","year":"2020","unstructured":"Berezin AE, Berezin AA, Lichtenauer M. Emerging role of adipocyte dysfunction in inducing heart failure among obese patients with prediabetes and known diabetes mellitus. Front Cardiovasc Med. 2020;7:583175.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"2707_CR86","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ehf2.14739","volume":"11","author":"Y Crum","year":"2024","unstructured":"Crum Y, Hoendermis ES, van Veldhuisen DJ, van Woerden G, Lobeek M, Dickinson MG, Meems LMG, Voors AA, Rienstra M, Gorter TM. Epicardial adipose tissue and pericardial constraint in heart failure with preserved ejection fraction. ESC Heart Fail. 2024;11(3):1698\u2013706.","journal-title":"ESC Heart Fail"},{"issue":"12","key":"2707_CR87","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1161\/CIRCRESAHA.124.323659","volume":"134","author":"P Alcaide","year":"2024","unstructured":"Alcaide P, Kallikourdis M, Emig R, Prabhu SD. Myocardial inflammation in heart failure with reduced and preserved ejection fraction. Circ Res. 2024;134(12):1752\u201366.","journal-title":"Circ Res"},{"issue":"17","key":"2707_CR88","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.jacc.2024.07.016","volume":"84","author":"J Dronkers","year":"2024","unstructured":"Dronkers J, van Veldhuisen DJ, van der Meer P, Meems LMG. Heart failure and obesity: unraveling molecular mechanisms of excess adipose tissue. J Am Coll Cardiol. 2024;84(17):1666\u201377.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2707_CR89","doi-asserted-by":"publisher","first-page":"e13820","DOI":"10.1111\/obr.13820","volume":"25","author":"A Paterek","year":"2024","unstructured":"Paterek A, Za\u0142\u0119ska-Koci\u0119cka M, Wojdy\u0144ska Z, Kalisz M, Litwiniuk A, Leszek P, M\u0105czewski M. Epicardial fat in heart failure-friend, foe, or bystander. Obes Rev. 2024;25(12):e13820.","journal-title":"Obes Rev"},{"key":"2707_CR90","doi-asserted-by":"crossref","unstructured":"Salvatore T, Galiero R, Caturano A, Vetrano E, Rinaldi L, Coviello F, Di Martino A, Albanese G, Colantuoni S, Medicamento G et al. Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes. Biomolecules 2022, 12(2).","DOI":"10.3390\/biom12020176"},{"issue":"5","key":"2707_CR91","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/heartjnl-2020-318242","volume":"108","author":"SL Ayton","year":"2022","unstructured":"Ayton SL, Gulsin GS, McCann GP, Moss AJ. Epicardial adipose tissue in obesity-related cardiac dysfunction. Heart. 2022;108(5):339\u201344.","journal-title":"Heart"},{"issue":"9","key":"2707_CR92","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","volume":"19","author":"G Iacobellis","year":"2022","unstructured":"Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19(9):593\u2013606.","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"2707_CR93","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/ejhf.2337","volume":"23","author":"NR Pugliese","year":"2021","unstructured":"Pugliese NR, Paneni F, Mazzola M, De Biase N, Del Punta L, Gargani L, Mengozzi A, Virdis A, Nesti L, Taddei S, et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail. 2021;23(11):1858\u201371.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"2707_CR94","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/ejhf.2513","volume":"24","author":"X Jin","year":"2022","unstructured":"Jin X, Hung CL, Tay WT, Soon D, Sim D, Sung KT, Loh SY, Lee S, Jaufeerally F, Ling LH, et al. Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction. Eur J Heart Fail. 2022;24(8):1346\u201356.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"2707_CR95","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/ehf2.14744","volume":"11","author":"A Schulz","year":"2024","unstructured":"Schulz A, Backhaus SJ, Lange T, Evertz R, Kutty S, Kowallick JT, Hasenfu\u00df G, Schuster A. Impact of epicardial adipose tissue on cardiac function and morphology in patients with diastolic dysfunction. ESC Heart Fail. 2024;11(4):2013\u201322.","journal-title":"ESC Heart Fail"},{"issue":"12","key":"2707_CR96","doi-asserted-by":"publisher","first-page":"101979","DOI":"10.1016\/j.cpcardiol.2023.101979","volume":"48","author":"A Wu","year":"2023","unstructured":"Wu A, Yang Z, Zhang X, Lin Z, Lu H. Association between epicardial adipose tissue and left atrial and ventricular function in patients with heart failure: a systematic review and Meta-Analysis. Curr Probl Cardiol. 2023;48(12):101979.","journal-title":"Curr Probl Cardiol"},{"issue":"5","key":"2707_CR97","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/ejhf.2156","volume":"23","author":"J Tromp","year":"2021","unstructured":"Tromp J, Bryant JA, Jin X, van Woerden G, Asali S, Yiying H, Liew OW, Ching JCP, Jaufeerally F, Loh SY, et al. Epicardial fat in heart failure with reduced versus preserved ejection fraction. Eur J Heart Fail. 2021;23(5):835\u20138.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"2707_CR98","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1001\/jamacardio.2024.0080","volume":"9","author":"JT R\u00e4m\u00f6","year":"2024","unstructured":"R\u00e4m\u00f6 JT, Kany S, Hou CR, Friedman SF, Roselli C, Nauffal V, Koyama S, Karjalainen J, Maddah M, Palotie A, et al. Cardiovascular significance and genetics of epicardial and pericardial adiposity. JAMA Cardiol. 2024;9(5):418\u201327.","journal-title":"JAMA Cardiol"},{"issue":"24","key":"2707_CR99","doi-asserted-by":"publisher","first-page":"e036789","DOI":"10.1161\/JAHA.124.036789","volume":"13","author":"W Wang","year":"2024","unstructured":"Wang W, Gao Y, Wang J, Ji C, Gu H, Yuan X, Yang S, Wang X. Prognostic value of epicardial adipose tissue in heart failure with Mid-Range and preserved ejection fraction: a multicenter study. J Am Heart Assoc. 2024;13(24):e036789.","journal-title":"J Am Heart Assoc"},{"key":"2707_CR100","doi-asserted-by":"crossref","unstructured":"Hsu JC, Huang KC, Lin TT, Lee JK, Su MM, Juang JJ, Wu CK, Lin LY. Epicardial adipose tissue is associated with geometry alteration and diastolic dysfunction in prediabetic cardiomyopathy. J Clin Endocrinol Metab 2024.","DOI":"10.1210\/clinem\/dgae400"},{"issue":"1","key":"2707_CR101","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/dom.14861","volume":"25","author":"L Nesti","year":"2023","unstructured":"Nesti L, Pugliese NR, Chiriac\u00f2 M, Trico D, Baldi S, Natali A. Epicardial adipose tissue thickness is associated with reduced peak oxygen consumption and systolic reserve in patients with type 2 diabetes and normal heart function. Diabetes Obes Metab. 2023;25(1):177\u201388.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2707_CR102","doi-asserted-by":"publisher","first-page":"127","DOI":"10.5543\/tkda.2021.65635","volume":"49","author":"B Uygur","year":"2021","unstructured":"Uygur B, \u00c7elik \u00d6, Demir AR, Karakayal\u0131 M, Arslan \u00c7, Otcu Temur H, Alis D, Y\u0131ld\u0131r\u0131m C, \u00c7\u00f6rek\u00e7io\u011flu B, Ert\u00fcrk M. Epicardial adipose tissue volume predicts long term major adverse cardiovascular events in patients with type 2 diabetes. Turk Kardiyol Dern Ars. 2021;49(2):127\u201334.","journal-title":"Turk Kardiyol Dern Ars"},{"issue":"9","key":"2707_CR103","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11906-024-01302-7","volume":"26","author":"A Dhore-Patil","year":"2024","unstructured":"Dhore-Patil A, Urina-Jassir D, Samson R, Le Jemtel TH, Oparil S. Epicardial adipose tissue thickness and preserved ejection fraction heart failure. Curr Hypertens Rep. 2024;26(9):381\u20138.","journal-title":"Curr Hypertens Rep"},{"key":"2707_CR104","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2147\/DMSO.S356001","volume":"15","author":"Z Liu","year":"2022","unstructured":"Liu Z, Hu W, Zhang H, Tao H, Lei P, Liu J, Yu Y, Dong Q, Gao L, Zhang D. EAT thickness as a predominant feature for evaluating arterial stiffness in patients with heart failure with preserved ejection fraction. Diabetes Metab Syndr Obes. 2022;15:1217\u201326.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"5","key":"2707_CR105","doi-asserted-by":"publisher","first-page":"107552","DOI":"10.1016\/j.jdiacomp.2020.107552","volume":"34","author":"Y Sugita","year":"2020","unstructured":"Sugita Y, Ito K, Sakurai S, Sakai S, Kuno S. Epicardial adipose tissue is tightly associated with exercise intolerance in patients with type 2 diabetes mellitus with asymptomatic left ventricular structural and functional abnormalities. J Diabetes Complications. 2020;34(5):107552.","journal-title":"J Diabetes Complications"},{"issue":"11","key":"2707_CR106","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1002\/ejhf.3011","volume":"25","author":"JF Chin","year":"2023","unstructured":"Chin JF, Aga YS, Abou Kamar S, Kroon D, Snelder SM, van de Poll SWE, Kardys I, Brugts JJ, de Boer RA, van Dalen BM. Association between epicardial adipose tissue and cardiac dysfunction in subjects with severe obesity. Eur J Heart Fail. 2023;25(11):1936\u201343.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2707_CR107","doi-asserted-by":"publisher","first-page":"e009238","DOI":"10.1161\/CIRCHEARTFAILURE.121.009238","volume":"15","author":"G van Woerden","year":"2022","unstructured":"van Woerden G, van Veldhuisen DJ, Manintveld OC, van Empel VPM, Willems TP, de Boer RA, Rienstra M, Westenbrink BD, Gorter TM. Epicardial adipose tissue and outcome in heart failure with Mid-Range and preserved ejection fraction. Circ Heart Fail. 2022;15(3):e009238.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"2707_CR108","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136(1):6\u201319.","journal-title":"Circulation"},{"issue":"1","key":"2707_CR109","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12933-023-01778-8","volume":"22","author":"J Liu","year":"2023","unstructured":"Liu J, Yu Q, Li Z, Zhou Y, Liu Z, You L, Tao L, Dong Q, Zuo Z, Gao L, et al. Epicardial adipose tissue density is a better predictor of cardiometabolic risk in HFpEF patients: a prospective cohort study. Cardiovasc Diabetol. 2023;22(1):45.","journal-title":"Cardiovasc Diabetol"},{"key":"2707_CR110","doi-asserted-by":"publisher","first-page":"111400","DOI":"10.1016\/j.ejrad.2024.111400","volume":"174","author":"SL Ayton","year":"2024","unstructured":"Ayton SL, Yeo JL, Gulsin GS, Dattani A, Bilak J, Deshpande A, Arnold JR, Singh A, Graham-Brown MPM, Ng L, et al. Association of epicardial adipose tissue with early structural and functional cardiac changes in type 2 diabetes. Eur J Radiol. 2024;174:111400.","journal-title":"Eur J Radiol"},{"issue":"1","key":"2707_CR111","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12916-023-02836-4","volume":"21","author":"M Choy","year":"2023","unstructured":"Choy M, Huang Y, Peng Y, Liang W, He X, Chen C, Li J, Zhu W, Wei FF, Dong Y, et al. Association between epicardial adipose tissue and incident heart failure mediating by alteration of natriuretic peptide and myocardial strain. BMC Med. 2023;21(1):117.","journal-title":"BMC Med"},{"key":"2707_CR112","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijcard.2022.05.067","volume":"362","author":"S He","year":"2022","unstructured":"He S, Zhu H, Zhang J, Wu X, Zhao L, Yang X. Proteomic analysis of epicardial adipose tissue from heart disease patients with concomitant heart failure with preserved ejection fraction. Int J Cardiol. 2022;362:118\u201325.","journal-title":"Int J Cardiol"},{"issue":"5","key":"2707_CR113","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1002\/ehf2.14748","volume":"11","author":"S He","year":"2024","unstructured":"He S, Zhao L, Zhang J, Yang X, Zhu H. Identification of molecular signatures in epicardial adipose tissue in heart failure with preserved ejection fraction. ESC Heart Fail. 2024;11(5):2510\u201320.","journal-title":"ESC Heart Fail"},{"issue":"2","key":"2707_CR114","doi-asserted-by":"publisher","first-page":"2267981","DOI":"10.1080\/07853890.2023.2267981","volume":"55","author":"L Zhao","year":"2023","unstructured":"Zhao L, Peng Y, Su P. Expression profiles and functional analysis of tRNA-derived small RNAs in epicardial adipose tissue of patients with heart failure. Ann Med. 2023;55(2):2267981.","journal-title":"Ann Med"},{"issue":"21","key":"2707_CR115","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1097\/CM9.0000000000001056","volume":"133","author":"ML Zheng","year":"2020","unstructured":"Zheng ML, Du XP, Zhao L, Yang XC. Expression profile of circular RNAs in epicardial adipose tissue in heart failure. Chin Med J Engl. 2020;133(21):2565\u201372.","journal-title":"Chin Med J Engl"},{"issue":"5","key":"2707_CR116","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/jcmm.17695","volume":"27","author":"Q Gao","year":"2023","unstructured":"Gao Q, He S, Peng Y, Su P, Zhao L. Proteomic profiling of epicardial fat in heart failure with preserved versus reduced and mildly reduced ejection fraction. J Cell Mol Med. 2023;27(5):727\u201335.","journal-title":"J Cell Mol Med"},{"issue":"12","key":"2707_CR117","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/ejhf.2741","volume":"24","author":"G van Woerden","year":"2022","unstructured":"van Woerden G, van Veldhuisen DJ, Westenbrink BD, de Boer RA, Rienstra M, Gorter TM. Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives. Eur J Heart Fail. 2022;24(12):2238\u201350.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2707_CR118","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12933-024-02376-y","volume":"23","author":"CD Yang","year":"2024","unstructured":"Yang CD, Quan JW, Tay GP, Feng S, Yuan H, Amuti A, Tang SY, Wu XR, Yuan RS, Lu L, et al. Epicardial adipose tissue volume and density are associated with heart failure with improved ejection fraction. Cardiovasc Diabetol. 2024;23(1):283.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"2707_CR119","doi-asserted-by":"publisher","first-page":"724","DOI":"10.4239\/wjd.v14.i6.724","volume":"14","author":"YJ Shi","year":"2023","unstructured":"Shi YJ, Dong GJ, Guo M. Targeting epicardial adipose tissue: a potential therapeutic strategy for heart failure with preserved ejection fraction with type 2 diabetes mellitus. World J Diabetes. 2023;14(6):724\u201340.","journal-title":"World J Diabetes"},{"issue":"18","key":"2707_CR120","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1093\/cvr\/cvac133","volume":"118","author":"NR Pugliese","year":"2023","unstructured":"Pugliese NR, Pellicori P, Filidei F, De Biase N, Maffia P, Guzik TJ, Masi S, Taddei S, Cleland JGF. Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovasc Res. 2023;118(18):3536\u201355.","journal-title":"Cardiovasc Res"},{"issue":"21","key":"2707_CR121","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.120.045810","volume":"142","author":"S Sanders-van Wijk","year":"2020","unstructured":"Sanders-van Wijk S, Tromp J, Beussink-Nelson L, Hage C, Svedlund S, Saraste A, Swat SA, Sanchez C, Njoroge J, Tan RS, et al. Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF study. Circulation. 2020;142(21):2029\u201344.","journal-title":"Circulation"},{"key":"2707_CR122","doi-asserted-by":"crossref","unstructured":"Smolgovsky S, Bayer AL, Kaur K, Sanders E, Aronovitz M, Filipp ME, Thorp EB, Schiattarella GG, Hill JA, Blanton RM et al. Impaired T cell IRE1\u03b1\/XBP1 signaling directs inflammation in experimental heart failure with preserved ejection fraction. J Clin Invest 2023, 133(24).","DOI":"10.1172\/JCI171874"},{"issue":"19","key":"2707_CR123","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1161\/CIRCULATIONAHA.122.062984","volume":"150","author":"C Panico","year":"2024","unstructured":"Panico C, Felicetta A, Kunderfranco P, Cremonesi M, Salvarani N, Carullo P, Colombo F, Idini A, Passaretti M, Doro R, et al. Single-cell RNA sequencing reveals metabolic stress-dependent activation of cardiac macrophages in a model of dyslipidemia-induced diastolic dysfunction. Circulation. 2024;150(19):1517\u201332.","journal-title":"Circulation"},{"issue":"7","key":"2707_CR124","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.cmet.2023.05.001","volume":"35","author":"BJ Jenkins","year":"2023","unstructured":"Jenkins BJ, Blagih J, Ponce-Garcia FM, Canavan M, Gudgeon N, Eastham S, Hill D, Hanlon MM, Ma EH, Bishop EL, et al. Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity. Cell Metab. 2023;35(7):1132\u2013e11461139.","journal-title":"Cell Metab"},{"issue":"2","key":"2707_CR125","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1084\/jem.20171274","volume":"215","author":"M Hulsmans","year":"2018","unstructured":"Hulsmans M, Sager HB, Roh JD, Valero-Mu\u00f1oz M, Houstis NE, Iwamoto Y, Sun Y, Wilson RM, Wojtkiewicz G, Tricot B, et al. Cardiac macrophages promote diastolic dysfunction. J Exp Med. 2018;215(2):423\u201340.","journal-title":"J Exp Med"},{"issue":"4","key":"2707_CR126","doi-asserted-by":"publisher","first-page":"e023800","DOI":"10.1161\/JAHA.121.023800","volume":"11","author":"XL Zhang","year":"2022","unstructured":"Zhang XL, Wang TY, Chen Z, Wang HW, Yin Y, Wang L, Wang Y, Xu B, Xu W. HMGB1-Promoted neutrophil extracellular traps contribute to cardiac diastolic dysfunction in mice. J Am Heart Assoc. 2022;11(4):e023800.","journal-title":"J Am Heart Assoc"},{"issue":"37","key":"2707_CR127","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1093\/eurheartj\/ehae517","volume":"45","author":"G Mang","year":"2024","unstructured":"Mang G, Chen J, Sun P, Ma R, Du J, Wang X, Cui J, Yang M, Tong Z, Yan X, et al. Von Willebrand factor exacerbates heart failure through formation of neutrophil extracellular traps. Eur Heart J. 2024;45(37):3853\u201367.","journal-title":"Eur Heart J"},{"issue":"18","key":"2707_CR128","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/eurheartj\/ehae205","volume":"45","author":"K Yang","year":"2024","unstructured":"Yang K, Gao R, Chen H, Hu J, Zhang P, Wei X, Shi J, Chen Y, Zhang L, Chen J, et al. Myocardial reperfusion injury exacerbation due to ALDH2 deficiency is mediated by neutrophil extracellular traps and prevented by leukotriene C4 Inhibition. Eur Heart J. 2024;45(18):1662\u201380.","journal-title":"Eur Heart J"},{"issue":"6731","key":"2707_CR129","doi-asserted-by":"publisher","first-page":"eadi3624","DOI":"10.1126\/science.adi3624","volume":"387","author":"M \u0160estan","year":"2025","unstructured":"\u0160estan M, Raposo B, Rendas M, Brea D, Pirzgalska R, Rasteiro A, Aliseychik M, Godinho I, Ribeiro H, Carvalho T, et al. Neuronal-ILC2 interactions regulate pancreatic glucagon and glucose homeostasis. Science. 2025;387(6731):eadi3624.","journal-title":"Science"},{"issue":"3","key":"2707_CR130","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/ejhf.1741","volume":"22","author":"B Pieske","year":"2020","unstructured":"Pieske B, Tsch\u00f6pe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the heart failure association (HFA) of the European society of cardiology (ESC). Eur J Heart Fail. 2020;22(3):391\u2013412.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2707_CR131","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","volume":"131","author":"SJ Shah","year":"2015","unstructured":"Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang C-C, Deo RC. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131(3):269\u201379.","journal-title":"Circulation"},{"issue":"3","key":"2707_CR132","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","volume":"8","author":"JB Cohen","year":"2020","unstructured":"Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, Yarde M, Wang Z, Bhattacharya PT, Chirinos DA, et al. Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail. 2020;8(3):172\u201384.","journal-title":"JACC Heart Fail"},{"issue":"12","key":"2707_CR133","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"16","key":"2707_CR134","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, Brunner-La Rocca H-P, Choi D-J, Chopra V, Chuquiure-Valenzuela E, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"key":"2707_CR135","doi-asserted-by":"crossref","unstructured":"Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, Di Salvo J, Epifani R, Marfella R, Docimo G et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci 2022, 23(7).","DOI":"10.3390\/ijms23073651"},{"issue":"1","key":"2707_CR136","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12933-024-02520-8","volume":"23","author":"Y Wen","year":"2024","unstructured":"Wen Y, Zhang X, Liu H, Ye H, Wang R, Ma C, Duo T, Wang J, Yang X, Yu M, et al. SGLT2 inhibitor downregulates ANGPTL4 to mitigate pathological aging of cardiomyocytes induced by type 2 diabetes. Cardiovasc Diabetol. 2024;23(1):430.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"2707_CR137","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, M\u00f8ller DV, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"15","key":"2707_CR138","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, M\u00f8ller DV, Treppendahl MB, Verma S, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394\u2013407.","journal-title":"N Engl J Med"},{"issue":"10","key":"2707_CR139","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jacbts.2023.05.012","volume":"8","author":"C Withaar","year":"2023","unstructured":"Withaar C, Meems LMG, Nollet EE, Schouten EM, Schroeder MA, Knudsen LB, Niss K, Madsen CT, Hoegl A, Mazzoni G, et al. The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF. JACC Basic Transl Sci. 2023;8(10):1298\u2013314.","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"2707_CR140","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40265-023-01992-4","volume":"84","author":"NL France","year":"2024","unstructured":"France NL, Syed YY. Tirzepatide: a review in type 2 diabetes. Drugs. 2024;84(2):227\u201338.","journal-title":"Drugs"},{"issue":"5","key":"2707_CR141","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02707-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02707-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02707-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T16:33:57Z","timestamp":1743957237000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02707-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":141,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2707"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02707-7","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}